Roosa E. Kallionpää
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Roosa E. Kallionpää has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
- Katja Valli
Department of Psychology and Speech-Language Pathology, and Turku Brain and Mind Center, University of Turku, Turku, Finland
7 shared publications Antti Revonsuo
Department of Psychology and Speech-Language Pathology, and Turku Brain and Mind Center, University of Turku, Turun yliopisto, Finland; Department of Cognitive Neuroscience and Philosophy, School of Bioscience, University of Skövde, Skövde, Sweden
4 shared publicationsA. Revonsuo
Department of Psychology and Speech-Language Pathology, and Turku Brain and Mind Center, University of Turku, Turku, Finland; Department of Cognitive Neuroscience and Philosophy, School of Bioscience, University of Skövde, Skövde, Sweden
3 shared publicationsA. Scheinin
Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland; Department of Perioperative Services, Intensive Care and Pain Medicine, Turku University Hospital, Turku, Finland
3 shared publicationsAnnalotta Scheinin
Department of Perioperative Services, Intensive Care and Pain Medicine, Turku University Hospital, Turku, Finland; Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland
3 shared publications- Carlos Rogerio Figueiredo
Medical Immune Oncology Research Group (MIORG), Institute of Biomedicine, Faculty of Medicine, University of Turku, Turku, Finland
3 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 104 (4) , e70153
Spatial Transcriptomic and Proteomic Analysis Identifies Novel Immune‐Associated Biomarkers of Anti‐ PD1 Response in Metastatic Melanoma
Resistance to anti‐PD1 therapy remains a major challenge in metastatic melanoma, despite long‐term benefit in some patients. Since a functional dendritic cell (DC)‐CD8 + T cell axis is essential for anti‐PD1 response, biomarkers associated with this axis may help characterize underexplored immune states linked to resistance. Here, we further characterized poor survival predictor (PSP) biomarkers previously negatively correlated with DC‐CD8 + T cell axis in melanoma, evaluating their associations with anti‐PD1 response, immune infiltration, and transcriptional and proteomic signatures. Pre‐treatment transcriptomic data were analysed using CIBERSORTx and Reactome, while NanoString GeoMx spatial transcriptomic and proteomic data were used to resolve biomarker‐associated features across tumour and immune compartments. We identified 28 PSP biomarkers significantly increased in non‐responsive patients with strong correlations with one another, suggesting coordinated transcriptional patterns within a tumour microenvironment unfavourable to therapeutic response and survival. These biomarkers were associated with immunosuppressive cell types, decreased cytotoxicity, and pathways related to transcription, translation, epigenetic regulation, and signal transduction. Spatially, PSP biomarkers were expressed in both tumour and immune compartments, but survival associations were compartment‐ and site‐specific. Among them, FAM57A , GSTA4 and KCTD1 were associated with poor survival when highly expressed in the CD45 + immune compartment of lymph node metastases. Their expression was associated with transcriptomic signatures of reduced immune activation, altered antigen presentation, and epigenetic regulation, and increased proteomic PI3K‐AKT‐mTORC1/MAPK signalling, especially upon co‐expression. Together, these results identify FAM57A , GSTA4 and KCTD1 as emerging immune‐associated biomarkers linked to established resistance‐associated immune states and poor prognosis in metastatic melanoma.
- 21 October 2026
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 104 (4) , e70153
Open AccessSpatial Transcriptomic and Proteomic Analysis Identifies Novel Immune‐Associated Biomarkers of Anti‐ PD1 Response in Metastatic Melanoma
Resistance to anti‐PD1 therapy remains a major challenge in metastatic melanoma, despite long‐term benefit in some patients. Since a functional dendritic cell (DC)‐CD8 + T cell axis is essential for anti‐PD1 response, biomarkers associated with this axis may help characterize underexplored immune states linked to resistance. Here, we further characterized poor survival predictor (PSP) biomarkers previously negatively correlated with DC‐CD8 + T cell axis in melanoma, evaluating their associations with anti‐PD1 response, immune infiltration, and transcriptional and proteomic signatures. Pre‐treatment transcriptomic data were analysed using CIBERSORTx and Reactome, while NanoString GeoMx spatial transcriptomic and proteomic data were used to resolve biomarker‐associated features across tumour and immune compartments. We identified 28 PSP biomarkers significantly increased in non‐responsive patients with strong correlations with one another, suggesting coordinated transcriptional patterns within a tumour microenvironment unfavourable to therapeutic response and survival. These biomarkers were associated with immunosuppressive cell types, decreased cytotoxicity, and pathways related to transcription, translation, epigenetic regulation, and signal transduction. Spatially, PSP biomarkers were expressed in both tumour and immune compartments, but survival associations were compartment‐ and site‐specific. Among them, FAM57A , GSTA4 and KCTD1 were associated with poor survival when highly expressed in the CD45 + immune compartment of lymph node metastases. Their expression was associated with transcriptomic signatures of reduced immune activation, altered antigen presentation, and epigenetic regulation, and increased proteomic PI3K‐AKT‐mTORC1/MAPK signalling, especially upon co‐expression. Together, these results identify FAM57A , GSTA4 and KCTD1 as emerging immune‐associated biomarkers linked to established resistance‐associated immune states and poor prognosis in metastatic melanoma.
- Open Access
- 8 July 2025
- Published by Springer Nature in Research Square
Novel Anti-PD1 Predictive Signature and Functional Dendritic-Cell Biomarkers in Melanoma Identified with Systems Immunology
Despite the success of anti-PD1 immunotherapy in melanoma, identifying biomarkers for response prediction and rational treatment combinations remains a major challenge. Effective dendritic cell (DC):CD8+ T cell crosstalk in the tumor microenvironment enhances anti-PD1 responses; however, no predictive signatures reflect this interaction. To address this, we developed a systems immunology approach based on DC:CD8+ T cell crosstalk reference biomarkers CD74 and CD8A, leading to the discovery of a 15-gene immune signature called PRIME, incorporated into a logistic regression framework for anti-PD1 response prediction in melanoma. PRIME outperforms previous signatures, especially in tumors with high CD8+ T cells, reflecting a functional immune response. Integrating clinical, molecular, spatial, and single-cell profiling identified SLAMF7 and TYMP as new functional biomarker candidates in DCs. Mechanistic studies revealed that these biomarkers regulate antigen processing and presentation in DCs. Our study demonstrates a new strategy for predicting anti-PD1 responses in melanoma, revealing biomarkers with functional roles that may inform future therapeutic development.
- 8 July 2025
- Published by Springer Nature in Research Square
Open AccessNovel Anti-PD1 Predictive Signature and Functional Dendritic-Cell Biomarkers in Melanoma Identified with Systems Immunology
Despite the success of anti-PD1 immunotherapy in melanoma, identifying biomarkers for response prediction and rational treatment combinations remains a major challenge. Effective dendritic cell (DC):CD8+ T cell crosstalk in the tumor microenvironment enhances anti-PD1 responses; however, no predictive signatures reflect this interaction. To address this, we developed a systems immunology approach based on DC:CD8+ T cell crosstalk reference biomarkers CD74 and CD8A, leading to the discovery of a 15-gene immune signature called PRIME, incorporated into a logistic regression framework for anti-PD1 response prediction in melanoma. PRIME outperforms previous signatures, especially in tumors with high CD8+ T cells, reflecting a functional immune response. Integrating clinical, molecular, spatial, and single-cell profiling identified SLAMF7 and TYMP as new functional biomarker candidates in DCs. Mechanistic studies revealed that these biomarkers regulate antigen processing and presentation in DCs. Our study demonstrates a new strategy for predicting anti-PD1 responses in melanoma, revealing biomarkers with functional roles that may inform future therapeutic development.
- 10 December 2024
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 134 (3) , 727-735
The relationship of bispectral index values to conscious state: an analysis of two volunteer cohort studies
- 10 December 2024
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 134 (3) , 727-735
The relationship of bispectral index values to conscious state: an analysis of two volunteer cohort studies
- Open Access
- 22 May 2024
- Published by Springer Nature in Genes & Immunity
- Vol. 25 (3) , 188-200
TIMP-1 is an activator of MHC-I expression in myeloid dendritic cells with implications for tumor immunogenicity
Immune checkpoint therapies (ICT) for advanced solid tumors mark a new milestone in cancer therapy. Yet their efficacy is often limited by poor immunogenicity, attributed to inadequate priming and generation of antitumor T cells by dendritic cells (DCs). Identifying biomarkers to enhance DC functions in such tumors is thus crucial. Tissue Inhibitor of Metalloproteinases-1 (TIMP-1), recognized for its influence on immune cells, has an underexplored relationship with DCs. Our research reveals a correlation between high TIMP1 levels in metastatic melanoma and increased CD8 + T cell infiltration and survival. Network studies indicate a functional connection with HLA genes. Spatial transcriptomic analysis of a national melanoma cohort revealed that TIMP1 expression in immune compartments associates with an HLA-A/MHC-I peptide loading signature in lymph nodes. Primary human and bone-marrow-derived DCs secrete TIMP-1, which notably increases MHC-I expression in classical type 1 dendritic cells (cDC1), especially under melanoma antigen exposure. TIMP-1 affects the immunoproteasome/TAP complex, as seen by upregulated PSMB8 and TAP-1 levels of myeloid DCs. This study uncovers the role of TIMP-1 in DC-mediated immunogenicity with insights into CD8 + T cell activation, providing a foundation for mechanistic exploration and highlighting its potential as a new target for combinatorial immunotherapy to enhance ICT effectiveness.
- 22 May 2024
- Published by Springer Nature in Genes & Immunity
- Vol. 25 (3) , 188-200
Open AccessTIMP-1 is an activator of MHC-I expression in myeloid dendritic cells with implications for tumor immunogenicity
Immune checkpoint therapies (ICT) for advanced solid tumors mark a new milestone in cancer therapy. Yet their efficacy is often limited by poor immunogenicity, attributed to inadequate priming and generation of antitumor T cells by dendritic cells (DCs). Identifying biomarkers to enhance DC functions in such tumors is thus crucial. Tissue Inhibitor of Metalloproteinases-1 (TIMP-1), recognized for its influence on immune cells, has an underexplored relationship with DCs. Our research reveals a correlation between high TIMP1 levels in metastatic melanoma and increased CD8 + T cell infiltration and survival. Network studies indicate a functional connection with HLA genes. Spatial transcriptomic analysis of a national melanoma cohort revealed that TIMP1 expression in immune compartments associates with an HLA-A/MHC-I peptide loading signature in lymph nodes. Primary human and bone-marrow-derived DCs secrete TIMP-1, which notably increases MHC-I expression in classical type 1 dendritic cells (cDC1), especially under melanoma antigen exposure. TIMP-1 affects the immunoproteasome/TAP complex, as seen by upregulated PSMB8 and TAP-1 levels of myeloid DCs. This study uncovers the role of TIMP-1 in DC-mediated immunogenicity with insights into CD8 + T cell activation, providing a foundation for mechanistic exploration and highlighting its potential as a new target for combinatorial immunotherapy to enhance ICT effectiveness.
- Open Access
- 22 April 2024
- Published by Wiley in International Journal of Cancer
- Vol. 155 (6) , 1112-1127
Cancer‐associated fibroblast activation predicts progression, metastasis, and prognosis of cutaneous squamous cell carcinoma
Cutaneous squamous cell carcinoma (cSCC) is the most common metastatic skin cancer and the metastatic disease is associated with poor prognosis. Cancer‐associated fibroblasts (CAFs) promote progression of cancer, but their role in cSCC is largely unknown. We examined the potential of CAF markers in the assessment of metastasis risk and prognosis of primary cSCC. We utilized multiplexed fluorescence immunohistochemistry for profiling CAF landscape in metastatic and non‐metastatic primary human cSCCs, in metastases, and in premalignant epidermal lesions. Quantitative high‐resolution image analysis was performed with two separate panels of antibodies for CAF markers and results were correlated with clinical and histopathological parameters including disease‐specific mortality. Increased stromal expression of fibroblast activation protein (FAP), α‐smooth muscle actin, and secreted protein acidic and rich in cysteine (SPARC) were associated with progression to invasive cSCC. Elevation of FAP and platelet‐derived growth factor receptor‐β (PDGFRβ) expression was associated with metastasis risk of primary cSCCs. High expression of PDGFRβ and periostin correlated with poor prognosis. Multimarker combination defined CAF subset, PDGFRα−/PDGFRβ+/FAP+, was associated with invasion and metastasis, and independently predicted poor disease‐specific survival. These results identify high PDGFRβ expression alone and multimarker combination PDGFRα−/PDGFRβ+/FAP+ by CAFs as potential biomarkers for risk of metastasis and poor prognosis.
- 22 April 2024
- Published by Wiley in International Journal of Cancer
- Vol. 155 (6) , 1112-1127
Open AccessCancer‐associated fibroblast activation predicts progression, metastasis, and prognosis of cutaneous squamous cell carcinoma
Cutaneous squamous cell carcinoma (cSCC) is the most common metastatic skin cancer and the metastatic disease is associated with poor prognosis. Cancer‐associated fibroblasts (CAFs) promote progression of cancer, but their role in cSCC is largely unknown. We examined the potential of CAF markers in the assessment of metastasis risk and prognosis of primary cSCC. We utilized multiplexed fluorescence immunohistochemistry for profiling CAF landscape in metastatic and non‐metastatic primary human cSCCs, in metastases, and in premalignant epidermal lesions. Quantitative high‐resolution image analysis was performed with two separate panels of antibodies for CAF markers and results were correlated with clinical and histopathological parameters including disease‐specific mortality. Increased stromal expression of fibroblast activation protein (FAP), α‐smooth muscle actin, and secreted protein acidic and rich in cysteine (SPARC) were associated with progression to invasive cSCC. Elevation of FAP and platelet‐derived growth factor receptor‐β (PDGFRβ) expression was associated with metastasis risk of primary cSCCs. High expression of PDGFRβ and periostin correlated with poor prognosis. Multimarker combination defined CAF subset, PDGFRα−/PDGFRβ+/FAP+, was associated with invasion and metastasis, and independently predicted poor disease‐specific survival. These results identify high PDGFRβ expression alone and multimarker combination PDGFRα−/PDGFRβ+/FAP+ by CAFs as potential biomarkers for risk of metastasis and poor prognosis.
- Open Access
- 31 May 2023
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 131 (2) , 348-359
Subjective experiences during dexmedetomidine- or propofol-induced unresponsiveness and non-rapid eye movement sleep in healthy male subjects
- 31 May 2023
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 131 (2) , 348-359
Open AccessSubjective experiences during dexmedetomidine- or propofol-induced unresponsiveness and non-rapid eye movement sleep in healthy male subjects
- 29 August 2022
- Published by Springer Nature in Nature Cell Biology
- Vol. 24 (9) , 1445
Publisher Correction: Cargo-specific recruitment in clathrin- and dynamin-independent endocytosis
- 29 August 2022
- Published by Springer Nature in Nature Cell Biology
- Vol. 24 (9) , 1445
Publisher Correction: Cargo-specific recruitment in clathrin- and dynamin-independent endocytosis
- Open Access
- 17 January 2022
- Published by Taylor & Francis in Annals of Medicine
- Vol. 54 (1) , 244-252
Increased incidence of melanoma in children and adolescents in Finland in 1990–2014: nationwide re-evaluation of histopathological characteristics
Changes in the incidence of melanoma in children and adolescents have been reported in Europe and in the USA in the recent decades.The aim of this study was to examine the incidence of paediatric a...
- 17 January 2022
- Published by Taylor & Francis in Annals of Medicine
- Vol. 54 (1) , 244-252
Open AccessIncreased incidence of melanoma in children and adolescents in Finland in 1990–2014: nationwide re-evaluation of histopathological characteristics
Changes in the incidence of melanoma in children and adolescents have been reported in Europe and in the USA in the recent decades.The aim of this study was to examine the incidence of paediatric a...
- 6 October 2021
- Published by Springer Nature in Nature Cell Biology
- Vol. 23 (10) , 1073-1084
Cargo-specific recruitment in clathrin- and dynamin-independent endocytosis
Spatially controlled, cargo-specific endocytosis is essential for development, tissue homeostasis and cancer invasion. Unlike cargo-specific clathrin-mediated endocytosis, the clathrin- and dynamin-independent endocytic pathway (CLIC-GEEC, CG pathway) is considered a bulk internalization route for the fluid phase, glycosylated membrane proteins and lipids. While the core molecular players of CG-endocytosis have been recently defined, evidence of cargo-specific adaptors or selective uptake of proteins for the pathway are lacking. Here we identify the actin-binding protein Swiprosin-1 (Swip1, EFHD2) as a cargo-specific adaptor for CG-endocytosis. Swip1 couples active Rab21-associated integrins with key components of the CG-endocytic machinery—Arf1, IRSp53 and actin—and is critical for integrin endocytosis. Through this function, Swip1 supports integrin-dependent cancer-cell migration and invasion, and is a negative prognostic marker in breast cancer. Our results demonstrate a previously unknown cargo selectivity for the CG pathway and a role for specific adaptors in recruitment into this endocytic route.
- 6 October 2021
- Published by Springer Nature in Nature Cell Biology
- Vol. 23 (10) , 1073-1084
Cargo-specific recruitment in clathrin- and dynamin-independent endocytosis
Spatially controlled, cargo-specific endocytosis is essential for development, tissue homeostasis and cancer invasion. Unlike cargo-specific clathrin-mediated endocytosis, the clathrin- and dynamin-independent endocytic pathway (CLIC-GEEC, CG pathway) is considered a bulk internalization route for the fluid phase, glycosylated membrane proteins and lipids. While the core molecular players of CG-endocytosis have been recently defined, evidence of cargo-specific adaptors or selective uptake of proteins for the pathway are lacking. Here we identify the actin-binding protein Swiprosin-1 (Swip1, EFHD2) as a cargo-specific adaptor for CG-endocytosis. Swip1 couples active Rab21-associated integrins with key components of the CG-endocytic machinery—Arf1, IRSp53 and actin—and is critical for integrin endocytosis. Through this function, Swip1 supports integrin-dependent cancer-cell migration and invasion, and is a negative prognostic marker in breast cancer. Our results demonstrate a previously unknown cargo selectivity for the CG pathway and a role for specific adaptors in recruitment into this endocytic route.
- Open Access
- 1 October 2020
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 125 (4) , 518-528
Alpha band frontal connectivity is a state-specific electroencephalographic correlate of unresponsiveness during exposure to dexmedetomidine and propofol
- 1 October 2020
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 125 (4) , 518-528
Open AccessAlpha band frontal connectivity is a state-specific electroencephalographic correlate of unresponsiveness during exposure to dexmedetomidine and propofol